arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Kura Oncology, Inc.

KURA
$9.58 ▲ +0.30 (+3.23%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
19 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
17
Health
Poor
Bearish
auto_awesome

Analytical Summary

Kura Oncology, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $839.9M
Dividend Yield
Revenue Growth 25.2%
Op. Margin -449.9%
ROIC -165.3%
FCF / Share $-0.81
Trailing P/E
Price / Book 4.8x
FCF Yield
Debt / Equity 0.06
info Valuation on last close. End-of-day price, Aug 7, 2026.

19-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$67.48M
↑ +25.2%
Net Income Profit after all expenses
$-278.67M
↓ -60.2%
Operating Margin Operating profit as % of sales
-449.9%
↓ -25.5% 0th
FCF / Share Free cash flow per share
$-0.81
↓ -151.9%
Long-Term Debt Long-term obligations
$9.70M
↑ +1.9%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
1
Returns
4
Financial Health
48
Cash Quality
31

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 19 years · 69 quarters